2. I've seen studies pointing to Arimidex being more effective in reducing estrone levels, but not as effective against peripheral aromatase conversion into estradiol. Blood tests I've seen on 1mg/day of Arimidex with 600-1000mg/week testosterone in a couple of users showed estradiol levels to be 3-4x above the reference range. Whereas Exemestane/aromasin is more effective at peripheral conversion. Have you seen anything to support this, and if so - that would perhaps indicate Arimidex being more suited for nandrolone cycles and Exemestane for testosterone cycles?
After a little reading I found some support for what i was saying with regard to the affinity of testosterone and nandrolone for aromatase here (http://www3.interscience.wiley.com/c...95662/PDFSTART). Also of note is that this paper as well as some others have shown aromatase to have preference for androstenedione over test. That leads me to believe that the higher doses of test may be too much for the dose of Arimidex. As far as exemestane, I am not seeing much showing a greater inhibition of peripheral conversion but it might make sense considering that exemestane is steroidal and might penetrate adipose more easily than nonsteroidal AI's. I do see several references showing exemestane to be less efficacious for reducing estradiol, estrone and estrone sulfate compared to arimidex and letrozole -- but these are all in women where peripheral conversion does not play as big a role as in men.